TORONTO, April 20, 2018 (GLOBE NEWSWIRE) -- Asian Mineral Resources Limited (“AMR” or the “Company”) (TSX-V:ASN) wishes to announce the decision to appoint Duncan Blount as a Director, replacing Kate Southwell, who has resigned from her role as Non-Executive Directo...Read More
Record contained metal production of 21.4 million ZnEq lbs, an increase of 9% over Q4 2017 and 57% over Q1 2017ZnEq grade of 6.1%, representing an increase of 15% over 5.3% ZnEq in Q4 2017 and 9% over Q1 2017 Cash balance of US$13.1 million at March 31, 2018 vs US$8.0 million at year end 2017Qua...Read More
TORONTO, April 16, 2018 (GLOBE NEWSWIRE) -- Asian Mineral Resources Limited (“AMR” or the “Company”) (TSX-V:ASN) advises shareholders that its Board of Directors (the “Board”) has continued exploring its strategic options with regard to the Ban Phuc Ni...Read More
TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) is very pleased to report the results of an updated Mineral Resource & Reserve Estimate for its El Mochito mine in Honduras prep...Read More
(All dollar amounts are in U.S. dollars (“$”) unless otherwise specified) Q4 2017 Highlights Positive Free Cash Flow of $0.75 million for Q4 2017 with $8.04 million in cash exiting 2017Adjusted EBITDA of $2.28 million for Q4 2017; six consecutive months of positive Adjusted EBIT...Read More
(All dollar amounts are in U.S. dollars (“$”) unless otherwise specified) Q4 2017 Highlights Positive Free Cash Flow of $0.75 million for Q4 2017 with $8.04 million in cash exiting 2017Adjusted EBITDA of $2.28 million for Q4 2017; six consecutive months of positive Adjusted EBIT...Read More
- Baseline demographics of TransCon Growth Hormone phase 3 heiGHt Trial presented - - Multiple ascending dose cohorts from TransCon PTH phase 1 clinical trial reinforced infusion-like profile over 24 hours - COPENHAGEN, Denmark, March 19, 2018 (GLOBE NEWSWIRE) -- Ascendis P...Read More
COPENHAGEN, Denmark, March 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will hold a conference call and...Read More
TORONTO, March 08, 2018 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) announced today that it plans to release its fourth quarter and year end 2017 results after the market close on Wednesday, March 21,...Read More
COPENHAGEN, Denmark, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,947,368 American Depositary Shares (“ADSs”), each of which represents one ord...Read More
COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares (“ADSs”), each of...Read More
COPENHAGEN, Denmark, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in an upc...Read More
TORONTO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) today issues a correction to the drilling results reported within the January 18, 2018 press release, with the updated informatio...Read More
NI 43-101 Technical Report targeting significant increase in mine life expected Q2 2018 TORONTO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) announces the results from an additio...Read More
Positive Free Cash Flow for Q4 2017 with US$8.0 million in cash exiting 2017Record tonnes milled in December; production increased by 81% since January 2017Guidance for 2018: Free Cash Flow of US$14-$20 million; EBITDA of US$32-$40 million TORONTO, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Ascendant...Read More
COPENHAGEN, Denmark, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today provided an update on its rare disease endocrinology pipelin...Read More
COPENHAGEN, Denmark, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced it has reached its target enrollment in the phase...Read More
COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in an upcoming i...Read More
TORONTO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Asian Mineral Resources Limited (the “Company”) (TSX-V: ASN) announces that 7,000,000 common shares of the Company have been issued to its Chief Executive Officer, Mr. Duncan Blount, pursuant to the terms of his employment agreement. ...Read More
Adjusted EBITDA1 of $1.6 million in NovemberRecord tonnes hoisted in November and Q4 production gains expected to drive robust operating and financial results in 2018Milled production tonnes up 67% year to date TORONTO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND)...Read More